Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Wilfred E Jaeger. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Wilfred E Jaeger har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:STIM / Neuronetics, Inc. | Director | 138 563 |
US:CNCE / Concert Pharmaceuticals Inc | Director | 0 |
US:NVRO / Nevro Corp. | Director | 9 592 |
US:ACRX / Talphera, Inc. | 10% Owner | 0 |
US:THLD / Threshold Pharmaceuticals, Inc. | Director | 35 000 |
US:LPDX / Liposcience Inc | 10% Owner | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Wilfred E Jaeger. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp STIM / Neuronetics, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i STIM / Neuronetics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-07-02 | STIM | JAEGER WILFRED E | 6 667 | 17,0000 | 6 667 | 17,0000 | 113 339 | 70 | 37.54 | 136 940 | 120,82 |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel STIM / Neuronetics, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i STIM / Neuronetics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp TLPH / Talphera, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i STIM / Neuronetics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel TLPH / Talphera, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i STIM / Neuronetics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Wilfred E Jaeger som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 36 364 | 138 563 | 35,58 | ||||
2023-03-06 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
D - Sale to Issuer | −16 400 | 0 | −100,00 | ||||
2023-03-06 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
U - Other | −5 125 | 0 | −100,00 | ||||
2022-06-13 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 16 400 | 21 525 | 320,00 | ||||
2022-05-31 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 38 910 | 102 187 | 61,49 | ||||
2021-06-11 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 250 | 10 250 | |||||
2021-06-11 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 125 | 5 125 | |||||
2021-06-01 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 7 137 | 63 289 | 12,71 | ||||
2020-08-07 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 18 513 | 56 152 | 49,19 | ||||
2020-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2020-05-28 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 20 000 | 37 639 | 113,39 | ||||
2020-05-26 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 376 | 9 592 | 16,75 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 2 085 | 3 106 | 204,21 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 2 085 | 3 106 | 204,21 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 714 | 25 341 | 2,90 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 16 302 | 25 341 | 180,35 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 1 021 | 3 106 | 48,97 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 1 021 | 3 106 | 48,97 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 349 | 25 341 | 1,40 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 7 976 | 25 341 | 45,93 | ||||
2020-01-06 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 3 062 | 17 639 | 21,01 | 4,49 | 13 748 | 79 199 | |
2019-10-03 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 1 957 | 14 577 | 15,51 | 8,30 | 16 243 | 120 989 | |
2019-07-02 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 1 298 | 12 620 | 11,46 | 12,51 | 16 238 | 157 876 | |
2019-06-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (Right to Buy) |
A - Award | 10 000 | 10 000 | |||||
2019-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Stock Option (right to buy) |
A - Award | 7 347 | 7 347 | |||||
2019-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 3 723 | 11 322 | 48,99 | ||||
2019-05-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 2 913 | 8 216 | 54,93 | ||||
2019-04-03 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 932 | 7 599 | 13,98 | 14,75 | 13 747 | 112 085 | |
2018-07-05 |
|
4 | STIM |
Neuronetics, Inc.
Stock Option (Right to Buy) |
A - Award | 8 767 | 8 767 | |||||
2018-07-05 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
P - Purchase | 6 667 | 6 667 | 17,00 | 113 339 | 113 339 | ||
2018-06-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (Right to Buy) |
A - Award | 10 000 | 10 000 | |||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −126 153 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −5 713 569 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −179 962 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −3 347 357 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 3 785 | 5 303 | 249,34 | ||||
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 461 | 11 042 | −11,69 | 81,42 | −118 958 | 899 064 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −66 125 | 500 109 | −11,68 | 81,42 | −5 384 043 | 40 719 975 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 098 | 12 503 | −8,07 | 80,38 | −88 258 | 1 005 000 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −49 742 | 566 234 | −8,08 | 80,38 | −3 998 297 | 45 514 285 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −910 | 13 601 | −6,27 | 80,19 | −72 969 | 1 090 610 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −41 206 | 615 976 | −6,27 | 80,19 | −3 304 144 | 49 392 652 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −216 | 14 511 | −1,47 | 80,48 | −17 385 | 1 167 908 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −9 784 | 657 182 | −1,47 | 80,48 | −787 458 | 52 892 833 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −151 | 14 727 | −1,01 | 81,36 | −12 286 | 1 198 226 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 832 | 666 966 | −1,01 | 81,36 | −555 869 | 54 266 021 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −173 | 14 878 | −1,15 | 83,09 | −14 375 | 1 236 276 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 844 | 673 798 | −1,15 | 83,09 | −651 791 | 55 988 706 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −286 | 15 051 | −1,86 | 83,20 | −23 795 | 1 252 212 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −12 972 | 681 642 | −1,87 | 83,20 | −1 079 243 | 56 711 183 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −26 | 15 337 | −0,17 | 84,17 | −2 188 | 1 290 954 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 174 | 694 614 | −0,17 | 84,17 | −98 819 | 58 467 397 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −286 | 20 764 | −1,36 | 90,31 | −25 829 | 1 875 201 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −12 935 | 940 387 | −1,36 | 90,31 | −1 168 162 | 84 926 538 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −70 | 21 050 | −0,33 | 89,72 | −6 280 | 1 888 503 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 176 | 953 322 | −0,33 | 89,72 | −284 935 | 85 527 379 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −158 | 21 120 | −0,74 | 87,00 | −13 746 | 1 837 440 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 156 | 956 498 | −0,74 | 87,00 | −622 572 | 83 215 326 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −112 | 21 278 | −0,52 | 87,01 | −9 745 | 1 851 433 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −5 094 | 963 654 | −0,53 | 87,01 | −443 237 | 83 849 076 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −432 | 21 390 | −1,98 | 86,48 | −37 360 | 1 849 820 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −19 568 | 968 748 | −1,98 | 86,48 | −1 692 252 | 83 777 908 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −432 | 21 822 | −1,94 | 85,17 | −36 795 | 1 858 650 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −19 568 | 988 316 | −1,94 | 85,17 | −1 666 669 | 84 178 036 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −540 | 22 254 | −2,37 | 84,44 | −45 600 | 1 879 228 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 460 | 1 007 884 | −2,37 | 84,44 | −2 065 512 | 85 110 260 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −331 | 22 794 | −1,43 | 84,02 | −27 810 | 1 915 125 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −15 012 | 1 032 344 | −1,43 | 84,02 | −1 261 290 | 86 736 304 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −236 | 23 125 | −1,01 | 84,04 | −19 834 | 1 943 462 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −10 701 | 1 047 356 | −1,01 | 84,04 | −899 329 | 88 021 474 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −299 | 23 361 | −1,26 | 82,75 | −24 743 | 1 933 155 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −13 501 | 1 058 057 | −1,26 | 82,75 | −1 117 227 | 87 555 698 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −641 | 23 660 | −2,64 | 82,54 | −52 905 | 1 952 797 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 024 | 1 071 558 | −2,64 | 82,54 | −2 395 519 | 88 441 897 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −546 | 24 301 | −2,20 | 82,40 | −44 991 | 2 002 407 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 709 | 1 100 582 | −2,20 | 82,40 | −2 036 027 | 90 688 177 | |
2017-06-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 545 | 3 545 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 518 | 1 518 | |||||
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −16 | 24 847 | −0,06 | 95,00 | −1 520 | 2 360 465 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −703 | 1 125 291 | −0,06 | 95,00 | −66 785 | 106 902 645 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 | 24 863 | −0,02 | 95,00 | −570 | 2 361 985 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −294 | 1 125 994 | −0,03 | 95,00 | −27 930 | 106 969 430 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −928 | 24 869 | −3,60 | 95,03 | −88 191 | 2 363 383 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −42 033 | 1 126 288 | −3,60 | 95,03 | −3 994 535 | 107 034 865 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −79 | 25 797 | −0,31 | 99,89 | −7 891 | 2 576 847 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −137 | 25 876 | −0,53 | 98,58 | −13 505 | 2 550 727 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 567 | 1 168 321 | −0,30 | 99,89 | −356 305 | 116 702 884 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 217 | 1 171 888 | −0,53 | 98,58 | −612 841 | 115 518 860 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −370 | 26 013 | −1,40 | 98,30 | −36 372 | 2 557 161 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 034 | 26 383 | −3,77 | 97,86 | −101 192 | 2 581 964 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −16 753 | 1 178 105 | −1,40 | 98,30 | −1 646 874 | 115 811 491 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −46 843 | 1 194 858 | −3,77 | 97,86 | −4 584 276 | 116 934 420 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −50 | 27 417 | −0,18 | 98,14 | −4 907 | 2 690 608 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 459 | 27 467 | −5,04 | 97,53 | −142 300 | 2 678 922 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −216 | 28 926 | −0,74 | 96,88 | −20 926 | 2 802 391 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 250 | 1 241 701 | −0,18 | 98,14 | −220 807 | 121 856 190 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −66 066 | 1 243 951 | −5,04 | 97,53 | −6 443 576 | 121 325 527 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −9 799 | 1 310 017 | −0,74 | 96,88 | −949 341 | 126 916 281 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −661 | 29 142 | −2,22 | 96,16 | −63 559 | 2 802 161 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 953 | 1 319 816 | −2,22 | 96,16 | −2 880 143 | 126 907 435 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −73 | 29 803 | −0,24 | 97,06 | −7 086 | 2 892 801 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −457 | 29 876 | −1,51 | 96,02 | −43 880 | 2 868 601 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 327 | 1 349 769 | −0,25 | 97,06 | −322 932 | 131 014 113 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −20 689 | 1 353 096 | −1,51 | 96,02 | −1 986 494 | 129 920 083 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −121 | 30 333 | −0,40 | 98,66 | −11 938 | 2 992 608 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 039 | 30 454 | −6,28 | 97,90 | −199 617 | 2 981 437 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −5 487 | 1 373 785 | −0,40 | 98,66 | −541 339 | 135 535 567 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −92 353 | 1 379 272 | −6,28 | 97,90 | −9 041 331 | 135 030 315 | |
2016-06-28 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 35 000 | 35 000 | |||||
2016-06-10 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2016-05-20 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 240 | 3 240 | |||||
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 | 32 493 | −0,09 | 64,02 | −1 857 | 2 080 182 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 314 | 1 471 625 | −0,09 | 64,02 | −84 121 | 94 212 550 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −78 | 32 522 | −0,24 | 65,54 | −5 112 | 2 131 365 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −174 | 32 600 | −0,53 | 64,01 | −11 137 | 2 086 628 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 522 | 1 472 939 | −0,24 | 65,54 | −230 818 | 96 530 678 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 866 | 1 476 461 | −0,53 | 64,01 | −503 479 | 94 503 839 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −91 | 32 774 | −0,28 | 65,47 | −5 957 | 2 145 609 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 069 | 32 865 | −5,92 | 64,68 | −133 813 | 2 125 544 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −4 140 | 1 484 327 | −0,28 | 65,47 | −271 033 | 97 174 139 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −93 700 | 1 488 467 | −5,92 | 64,68 | −6 060 048 | 96 266 603 | |
2016-03-01 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
J - Other | −27 500 | 52 500 | −34,38 | ||||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −113 | 0 | −100,00 | 19,57 | −2 211 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 066 | 0 | −100,00 | 19,57 | −99 119 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −265 | 0 | −100,00 | 19,57 | −5 185 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −4 916 | 0 | −100,00 | 19,57 | −96 184 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −589 | 113 | −83,90 | 20,10 | −11 841 | 2 272 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −26 697 | 5 066 | −84,05 | 20,10 | −536 719 | 101 847 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 392 | 265 | −84,01 | 20,10 | −27 985 | 5 328 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −25 894 | 4 916 | −84,04 | 20,10 | −520 576 | 98 832 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −42 | 702 | −5,65 | 20,09 | −844 | 14 102 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 919 | 31 763 | −5,70 | 20,09 | −38 549 | 638 058 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −100 | 1 657 | −5,69 | 20,09 | −2 009 | 33 286 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 861 | 30 810 | −5,70 | 20,09 | −37 384 | 618 914 | |
2015-11-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −540 | 34 934 | −1,52 | 53,48 | −28 880 | 1 868 312 | |
2015-11-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 460 | 1 582 167 | −1,52 | 53,48 | −1 308 150 | 84 616 190 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −696 | 35 474 | −1,92 | 53,16 | −36 999 | 1 885 773 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 040 | 36 170 | −5,34 | 52,08 | −106 237 | 1 883 618 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −31 496 | 1 606 627 | −1,92 | 53,16 | −1 674 305 | 85 407 167 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −92 400 | 1 638 123 | −5,34 | 52,08 | −4 811 896 | 85 308 204 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 045 | 38 210 | −2,66 | 51,94 | −54 276 | 1 984 589 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −47 323 | 1 730 523 | −2,66 | 51,94 | −2 457 909 | 89 881 634 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 296 | 744 | −63,53 | 18,22 | −23 613 | 13 556 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −58 704 | 33 682 | −63,54 | 18,22 | −1 069 587 | 613 686 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −3 062 | 1 757 | −63,54 | 18,22 | −55 790 | 32 013 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −56 938 | 32 671 | −63,54 | 18,22 | −1 037 410 | 595 266 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 805 | 2 040 | −76,94 | 15,70 | −106 838 | 32 028 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −308 195 | 92 386 | −76,94 | 15,70 | −4 838 662 | 1 450 460 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −16 071 | 4 819 | −76,93 | 15,70 | −252 315 | 75 658 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −298 929 | 89 609 | −76,94 | 15,70 | −4 693 185 | 1 406 861 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 404 | 8 845 | −13,70 | 16,32 | −22 913 | 144 350 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −63 596 | 400 581 | −13,70 | 16,32 | −1 037 887 | 6 537 482 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −3 316 | 20 890 | −13,70 | 16,32 | −54 117 | 340 925 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −61 684 | 388 538 | −13,70 | 16,32 | −1 006 683 | 6 340 940 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −996 | 10 249 | −8,86 | 16,75 | −16 683 | 171 671 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −45 112 | 464 177 | −8,86 | 16,75 | −755 626 | 7 774 965 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 352 | 24 206 | −8,86 | 16,75 | −39 396 | 405 450 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −43 755 | 450 222 | −8,86 | 16,75 | −732 896 | 7 541 218 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 056 | 11 245 | −8,58 | 14,49 | −15 301 | 162 937 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −47 837 | 509 289 | −8,59 | 14,49 | −693 144 | 7 379 445 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 494 | 26 558 | −8,58 | 14,49 | −36 137 | 384 817 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −46 398 | 493 977 | −8,59 | 14,49 | −672 293 | 7 157 579 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 056 | 11 245 | −8,58 | 17,49 | −18 469 | 196 672 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −47 837 | 509 289 | −8,59 | 17,49 | −836 655 | 8 907 312 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 494 | 26 558 | −8,58 | 17,49 | −43 619 | 464 491 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −46 398 | 493 977 | −8,59 | 17,49 | −811 487 | 8 639 510 | |
2015-07-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2015-06-15 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2015-06-08 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −8 500 | 39 255 | −17,80 | 47,94 | −407 490 | 1 881 885 | |
2015-06-08 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −384 968 | 1 777 846 | −17,80 | 47,94 | −18 455 366 | 85 229 937 | |
2015-06-01 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 4 182 | 4 182 | |||||
2015-02-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock Warrant (Right to Buy) |
P - Purchase | 25 000 | 25 000 | |||||
2015-02-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 25 000 | 80 000 | 45,45 | 3,74 | 93 625 | 299 600 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 400 | 12 301 | −30,51 | 12,29 | −66 366 | 151 179 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −244 600 | 557 126 | −30,51 | 12,29 | −3 006 134 | 6 847 079 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −12 755 | 29 052 | −30,51 | 12,29 | −156 759 | 357 049 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −237 245 | 540 375 | −30,51 | 12,29 | −2 915 741 | 6 641 209 | |
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series C Preferred Stock |
C - Conversion | −4 506 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series B Preferred Stock |
C - Conversion | −15 069 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series A Preferred Stock |
C - Conversion | −28 090 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series C Preferred Stock |
C - Conversion | −204 076 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series B Preferred Stock |
C - Conversion | −682 475 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series A Preferred Stock |
C - Conversion | −1 272 187 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 4 506 | 47 755 | 10,42 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 15 069 | 43 249 | 53,47 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 28 090 | 28 180 | 31 211,11 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 204 076 | 2 162 814 | 10,42 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 682 475 | 1 958 738 | 53,47 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 1 272 187 | 1 276 263 | 31 211,65 | ||||
2014-11-07 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 8 477 | 8 477 | |||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-05-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −391 359 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −1 956 794 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −1 467 595 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −8 641 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −43 206 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −32 405 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 101 264 | 801 726 | 14,46 | 14,00 | 1 417 696 | 11 224 164 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 2 236 | 17 701 | 14,46 | 14,00 | 31 304 | 247 814 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 69 267 | 700 462 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 346 335 | 631 195 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 259 751 | 284 860 | 1 034,49 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 1 529 | 15 465 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 7 647 | 13 936 | 121,59 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 5 735 | 6 289 | 1 035,20 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −379 592 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −1 897 959 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −1 423 469 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −20 408 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −102 041 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −76 531 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 98 219 | 777 620 | 14,46 | 14,00 | 1 375 066 | 10 886 680 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 5 281 | 41 807 | 14,46 | 14,00 | 73 934 | 585 298 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 67 184 | 679 401 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 335 922 | 612 217 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 251 941 | 276 295 | 1 034,50 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 3 612 | 36 526 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 18 060 | 32 914 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 13 545 | 14 854 | 1 034,76 | ||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-01-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 907 | 0 | −100,00 | 4,86 | −23 832 | ||
2014-01-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −91 449 | 0 | −100,00 | 4,86 | −444 140 | ||
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 204 | 4 907 | −67,53 | 4,86 | −49 561 | 23 833 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −189 796 | 91 449 | −67,48 | 4,86 | −921 839 | 444 168 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 000 | 15 111 | −24,86 | 4,87 | −24 330 | 73 530 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −93 000 | 281 245 | −24,85 | 4,87 | −452 538 | 1 368 538 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 477 | 20 111 | −24,36 | 4,90 | −31 705 | 98 443 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −120 479 | 374 245 | −24,35 | 4,90 | −589 745 | 1 831 929 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −14 286 | 26 588 | −34,95 | 4,87 | −69 597 | 129 529 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −265 714 | 494 724 | −34,94 | 4,87 | −1 294 479 | 2 410 147 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 204 | 40 874 | −19,98 | 4,87 | −49 668 | 198 954 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −189 796 | 760 438 | −19,97 | 4,87 | −923 832 | 3 701 432 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −12 444 | 51 078 | −19,59 | 4,90 | −60 957 | 250 206 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −231 456 | 950 234 | −19,59 | 4,90 | −1 133 787 | 4 654 721 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 552 | 63 522 | −6,69 | 5,52 | −25 118 | 350 514 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −84 648 | 1 181 690 | −6,68 | 5,52 | −467 088 | 6 520 565 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −11 877 | 68 074 | −14,86 | 5,54 | −65 787 | 377 062 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −220 923 | 1 266 338 | −14,85 | 5,54 | −1 223 692 | 7 014 246 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 918 | 79 951 | −6,89 | 5,52 | −32 672 | 441 385 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −110 082 | 1 487 261 | −6,89 | 5,52 | −607 730 | 8 210 722 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 163 | 85 869 | −3,55 | 5,50 | −17 400 | 472 374 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −58 837 | 1 597 343 | −3,55 | 5,50 | −323 668 | 8 787 144 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 897 | 89 032 | −5,21 | 5,48 | −26 836 | 487 895 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −91 070 | 1 656 180 | −5,21 | 5,48 | −499 064 | 9 075 866 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 311 | 93 929 | −6,30 | 5,56 | −35 089 | 522 245 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −117 389 | 1 747 250 | −6,30 | 5,56 | −652 683 | 9 714 710 | |
2013-06-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −102 | 100 240 | −0,10 | 5,50 | −561 | 551 671 | |
2013-06-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 898 | 1 864 639 | −0,10 | 5,50 | −10 446 | 10 262 041 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 649 | 100 342 | −3,51 | 5,50 | −20 075 | 552 021 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −67 862 | 1 866 537 | −3,51 | 5,50 | −373 336 | 10 268 567 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 715 | 103 991 | −2,54 | 5,53 | −15 006 | 574 758 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −50 507 | 1 934 399 | −2,54 | 5,53 | −279 152 | 10 691 423 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 735 | 106 706 | −2,50 | 5,50 | −15 043 | 586 915 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −50 865 | 1 984 906 | −2,50 | 5,50 | −279 773 | 10 917 578 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 102 | 109 441 | −4,45 | 5,47 | −27 893 | 598 325 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −94 898 | 2 035 771 | −4,45 | 5,47 | −518 817 | 11 129 764 | |
2013-05-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series F Convertible Preferred Stock |
C - Conversion | −25 261 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series F Convertible Preferred Stock |
C - Conversion | −534 339 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series E Convertible Preferred Stock |
C - Conversion | −41 509 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series E Convertible Preferred Stock |
C - Conversion | −878 030 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock |
C - Conversion | −69 183 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock |
C - Conversion | −1 463 385 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
P - Purchase | 9 705 | 83 739 | 13,11 | 9,00 | 87 345 | 753 651 | |
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
P - Purchase | 205 295 | 1 771 347 | 13,11 | 9,00 | 1 847 655 | 15 942 123 | |
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
C - Conversion | 72 646 | 74 034 | 5 233,86 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
C - Conversion | 1 536 688 | 1 566 052 | 5 233,24 | ||||
2013-01-24 | 3 | LPDX |
LIPOSCIENCE INC
Common Stock |
29 364 | ||||||||
2013-01-24 | 3 | LPDX |
LIPOSCIENCE INC
Common Stock |
1 388 | ||||||||
2012-12-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 52 213 | 139 621 | 59,73 | 3,31 | 172 825 | 462 146 | |
2012-12-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 364 705 | 6 323 534 | 59,73 | 3,31 | 7 827 174 | 20 930 898 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −12 500 | 20 000 | −38,46 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −12 500 | 20 000 | −38,46 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −10 000 | 45 000 | −18,18 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −10 000 | 45 000 | −18,18 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 55 000 | −4,35 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 55 000 | −4,35 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 57 500 | −4,17 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 60 000 | −4,00 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 500 | 55 000 | 29,41 | 1,64 | 20 500 | 90 200 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 500 | 42 500 | 41,67 | 1,62 | 20 250 | 68 850 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 30 000 | 50,00 | 1,95 | 19 500 | 58 500 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 20 000 | 14,29 | 1,30 | 3 250 | 26 000 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 20 000 | 14,29 | 1,30 | 3 250 | 26 000 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 15 000 | 20,00 | 1,30 | 3 250 | 19 500 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 12 500 | 25,00 | 1,30 | 3 250 | 16 250 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 10 000 | 0,79 | 7 900 | 7 900 | ||
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −14 612 | 114 543 | −11,31 | 7,98 | −116 566 | 913 755 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −271 788 | 2 129 669 | −11,32 | 7,98 | −2 168 162 | 16 989 221 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −25 510 | 129 155 | −16,49 | 8,02 | −204 649 | 1 036 120 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −474 490 | 2 401 457 | −16,50 | 8,02 | −3 806 501 | 19 265 208 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 990 | 154 665 | −1,90 | 7,52 | −22 473 | 1 162 493 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −56 610 | 2 875 947 | −1,93 | 7,52 | −425 492 | 21 616 193 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 531 | 157 655 | −0,96 | 7,50 | −11 482 | 1 182 412 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −28 469 | 2 932 557 | −0,96 | 7,50 | −213 518 | 21 994 178 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −21 369 | 0 | −100,00 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −20 007 | 21 369 | −48,35 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −397 478 | 0 | −100,00 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −372 149 | 397 478 | −48,35 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 21 369 | 159 186 | 15,51 | 2,05 | 43 806 | 326 331 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 20 007 | 137 817 | 16,98 | 1,86 | 37 213 | 256 340 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 397 478 | 2 961 026 | 15,50 | 2,05 | 814 830 | 6 070 103 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 372 149 | 2 563 548 | 16,98 | 1,86 | 692 197 | 4 768 199 | |
2012-07-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 377 | 117 810 | −5,13 | 8,01 | −51 101 | 944 047 | |
2012-07-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −118 623 | 2 191 399 | −5,14 | 8,01 | −950 562 | 17 560 338 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 4 151 | 4 151 | 0,12 | 519 | 519 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 188 020 | 188 020 | 0,12 | 23 502 | 23 502 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 3 268 | 3 268 | 0,12 | 408 | 408 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 60 789 | 60 789 | 0,12 | 7 599 | 7 599 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4 613 | 87 408 | 5,57 | 3,40 | 15 684 | 297 187 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 208 911 | 3 958 829 | 5,57 | 3,40 | 710 297 | 13 460 019 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3 631 | 199 174 | 1,86 | 3,40 | 12 345 | 677 192 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 67 543 | 3 704 712 | 1,86 | 3,40 | 229 646 | 12 596 021 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 4 151 | 4 151 | 0,12 | 519 | 519 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 188 020 | 188 020 | 0,12 | 23 502 | 23 502 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 3 268 | 3 268 | 0,12 | 408 | 408 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 60 789 | 60 789 | 0,12 | 7 599 | 7 599 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4 613 | 87 408 | 5,57 | 3,40 | 15 684 | 297 187 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 208 911 | 3 958 829 | 5,57 | 3,40 | 710 297 | 13 460 019 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3 631 | 199 174 | 1,86 | 3,40 | 12 345 | 677 192 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 67 543 | 3 704 712 | 1,86 | 3,40 | 229 646 | 12 596 021 | |
2012-05-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2007-05-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2006-03-07 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 000 000 | 2 440 202 | −29,07 | 14,50 | −14 500 000 | 35 382 929 | |
2005-02-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 11 939 | 175 491 | 7,30 | 7,00 | 83 573 | 1 228 437 | |
2005-02-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 222 059 | 3 264 711 | 7,30 | 7,00 | 1 554 413 | 22 852 977 | |
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | −154 607 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | −2 875 696 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | −114 750 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | −2 135 250 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 93 877 | 163 552 | 134,74 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1 746 126 | 3 042 652 | 134,68 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 69 675 | 69 675 | |||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1 296 526 | 1 296 526 |